Cecilia Pessoa Gingerich

Additionally, guideline adherence in antibiotic prescribing was lower for telemedicine visits than in primary care or urgent care settings.

Both long-acting injectable treatments produced statistically significant and clinically meaningful improvements.

The SIRA RFA Electrosurgical Device is used in electrosurgery for intraoperative coagulation and soft tissue ablation.

Dovato is a 2-drug regimen approved for treatment-naïve adult patients with HIV infection.

Investigators have found that despite improvements in women’s cardiovascular health care, black women still face disparities in care compared to white and Hispanic women.

By applying research-supported practices, Optimal Hospital has increased patient sleep, improved HCAHPS scores, and decreased length of stay and readmissions.

An extended-release, subcutaneous injection form of buprenorphine (Sublocade) demonstrated long-term efficacy and safety results.

Patients in the Optimal Hospital wing are given iPads that let them access their medical records, see their care team, and view the schedule of their upcoming tests.

New features include wireless vital monitors, red lighting for nighttime, and surfaces and linens infused with antimicrobial copper.

Ochsner Medical Center's innovative Optimal Hospital initiative has sought to reduce hospital-acquired infections, length of stay, and readmissions.

Endometrial ablation with the Cerene Device does not require general anesthesia and can be performed in a gynecologist’s office.

The Complete Response Letter highlights issues in the Chemistry, Manufacturing, and Controls section of the application.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.

A fourth phase 3 study of investigational drug SPN-812 demonstrated a significant decrease in ADHD-RS-5 scores compared to placebo.

The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

Higher exposure to air pollutants, especially NO2 and NOx, was found to be associated with greater odds of psychotic experiences in adolescents.

The investigational anti-fibrotic immunomodulator is being investigated for respiratory, oncology, hepatology, and nephrology indications.

One evaluated dose of AVP-786 significantly improved scores in patients with moderate-to-severe agitation related to Alzheimer dementia, compared to placebo.

Modeling showed that waiting until October to vaccinate would reduce flu cases in older adults, provided vaccination rates don’t decrease and flu season doesn’t peak early.

The FDA’s response noted that the onset and duration of intravenous meloxicam would not meet prescriber expectations for an IV drug.

The FDA’s decision regarding sotagliflozin (Zynquista), an investigational treatment for type 1 diabetes, followed a split Advisory Committee vote in January.

The breakthrough device is indicated to improve 6-minute walk distance for certain patients with chronic heart failure.

The applications seek FDA approval for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes.

The oral immunotherapy seeks approval as a treatment to reduce the risk of anaphylaxis in peanut-allergic children and adolescents following exposure to peanut.

Among participants of the EMPA-REG OUTCOME trial who experienced heart failure, empagliflozin was associated with lower rates of short-term re-hospitalization and death.

Admissions for infective endocarditis related to intravenous drug use increased 436% from 2012-2017 at an Ohio medical center.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.